China Approves Leqembi Subcutaneous Autoinjector for Early Alzheimer's

China's NMPA approved Eisai's Leqembi SC-AI for early Alzheimer's, expanding access to a key treatment in a major market. This follows prior approvals of the IV formulation and marks a shift toward more convenient at-home administration. The approval could boost Bioarctic's royalty revenue and strengthen Eisai's competitive position in China's growing Alzheimer's drug market.